Loading clinical trials...

Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years | Clinical Trials | Clareo Health

COMPLETED

Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years

Open-label, Uncontrolled, Prospective Long-term Observation of Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years

NCT01389271•Bayer

View on ClinicalTrials.gov

Summary

This is an open-label, uncontrolled, prospective long-term observation of Specific Drug in the treatment of patients with pulmonary hypertension up to 4 years. 160 patients with primary (idiopathic and familial) pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) due to scleroderma with New York Heart Association (NYHA) functional class and exercise capacity, defined as class III and IV planned to enroll. Efficacy, safety and tolerability of the drug and the survival of the patients will be observed.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients who has pulmonary hypertension treated with inhaled iloprost older than 18 years old.
•Primary (idiopathic and familial) pulmonary hypertension (PH) with New York Heart Association (NYHA) functional class and exercise capacity, defined as class III and IV.
•Pulmonary arterial hypertension (PAH) due to scleroderma with New York Heart Association (NYHA) functional class and exercise capacity, defined as class III and IV.
•Patients who signed written informed consent.

Exclusion Criteria

•Severe coronary heart disease or unstable angina; Myocardial infarction within the last six months; Decompensated cardiac failure if not under close medical supervision;
•Severe arrhythmias;
•Cerebrovascular events (e.g. transient ischaemic attack, stroke) within the last 3 months.
•Pulmonary hypertension due to venous occlusive disease.
•Congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension.
•Pregnancy and lactation
•Age below 18

Locations (1)

Multiple Locations, Turkey (Türkiye)

Key Dates

Start Date

February 3, 2011

Primary Completion Date

March 8, 2017

Completion Date

June 18, 2018

Last Updated

April 25, 2019

Enrollment

118

ACTUAL participants

Conditions

Pulmonary Hypertension

Interventions

Ventavis inhaled (Iloprost, BAYQ6256)

DRUG

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820

Pulmonary Hypertension

View study

RECRUITINGPHASE1

Preliminary Human Trials of F230 Tablets

NCT06899815

Pulmonary Hypertension

View study

RECRUITINGPHASE2/PHASE3

Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 25, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years

Inclusion Criteria

Exclusion Criteria

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Preliminary Human Trials of F230 Tablets

Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

Prospective Evaluation of AI-ECG for SHD Detection

Pulmonary Hypertension in Left Heart Disease

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH